These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32817674)

  • 1. Challenges and prospects of snake antivenom supply in sub-Saharan Africa.
    Habib AG; Musa BM; Iliyasu G; Hamza M; Kuznik A; Chippaux JP
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008374. PubMed ID: 32817674
    [No Abstract]   [Full Text] [Related]  

  • 2. Consequences of neglect: analysis of the sub-Saharan African snake antivenom market and the global context.
    Brown NI
    PLoS Negl Trop Dis; 2012; 6(6):e1670. PubMed ID: 22679521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new Pan African polyspecific antivenom developed in response to the antivenom crisis in Africa.
    Laing GD; Renjifo JM; Ruiz F; Harrison RA; Nasidi A; Gutierrez JM; Rowley PD; Warrell DA; Theakston RD
    Toxicon; 2003 Jul; 42(1):35-41. PubMed ID: 12893059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of preclinical efficacy testing of antivenoms for sub-Saharan Africa: Inadequate independent scrutiny and poor-quality reporting are barriers to improving snakebite treatment and management.
    Ainsworth S; Menzies SK; Casewell NR; Harrison RA
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008579. PubMed ID: 32817682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Snake bites and antivenom shortage in Africa.
    Chippaux JP; Massougbodji A; Diouf A; Baldé CM; Boyer LV
    Lancet; 2015 Dec; 386(10010):2252-3. PubMed ID: 26681284
    [No Abstract]   [Full Text] [Related]  

  • 6. [An unusual mode of snake poisoning in Tunisia].
    Chaari AN; Bahloul M; Tlijani M; Dammak H; Bouaziz M
    Med Trop (Mars); 2010 Apr; 70(2):201-2. PubMed ID: 20486364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?
    Laustsen AH; Johansen KH; Engmark M; Andersen MR
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005361. PubMed ID: 28158193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bringing antivenoms to Sub-Saharan Africa.
    Stock RP; Massougbodji A; Alagón A; Chippaux JP
    Nat Biotechnol; 2007 Feb; 25(2):173-7. PubMed ID: 17287747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omics meets biology: application to the design and preclinical assessment of antivenoms.
    Calvete JJ; Sanz L; Pla D; Lomonte B; Gutiérrez JM
    Toxins (Basel); 2014 Dec; 6(12):3388-405. PubMed ID: 25517863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reviewing evidence of the clinical effectiveness of commercially available antivenoms in sub-Saharan Africa identifies the need for a multi-centre, multi-antivenom clinical trial.
    Potet J; Smith J; McIver L
    PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007551. PubMed ID: 31233536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of the availability and use of antivenom in the district of Bamako, Mali, West Africa].
    Dramé BS; Dabo M; Diani N; Cissé B
    Bull Soc Pathol Exot; 2012 Aug; 105(3):179-83. PubMed ID: 22707256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of Snakebites in Sub-Saharan Africa].
    Chippaux JP
    Med Sante Trop; 2015; 25(3):245-8. PubMed ID: 26039508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Guidelines for the production, control and regulation of snake antivenom immunoglobulins].
    Chippaux JP
    Biol Aujourdhui; 2010; 204(1):87-91. PubMed ID: 20950580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross neutralization of dangerous snake venoms from Africa and the Middle East using the VACSERA polyvalent antivenom. Egyptian Organization for Biological Products & Vaccines.
    Seddik SS; Wanas S; Helmy MH; Hashem M
    J Nat Toxins; 2002 Dec; 11(4):329-35. PubMed ID: 12503876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Call for global snake-bite control and procurement funding.
    Cheng AC; Winkel K
    Lancet; 2001 Apr; 357(9262):1132. PubMed ID: 11303611
    [No Abstract]   [Full Text] [Related]  

  • 16. Timing of the administration of antivenom.
    Eddington JA; Wingert WA
    Toxicon; 1986; 24(5):421-3. PubMed ID: 3715906
    [No Abstract]   [Full Text] [Related]  

  • 17. IgG subclass distributions of anti-horse serum antibodies and natural venom-antibodies produced in response to antivenom injection or snake bite in humans.
    Ameno S; Ameno K; Fuke C; Kiryu T; Ijiri I
    Toxicon; 1990; 28(3):347-50. PubMed ID: 2343468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New techniques in antivenom production and active immunization against snake venoms.
    Theakston RD
    Trans R Soc Trop Med Hyg; 1989; 83(4):433-5. PubMed ID: 2694474
    [No Abstract]   [Full Text] [Related]  

  • 19. The need for full integration of snakebite envenoming within a global strategy to combat the neglected tropical diseases: the way forward.
    Gutiérrez JM; Warrell DA; Williams DJ; Jensen S; Brown N; Calvete JJ; Harrison RA;
    PLoS Negl Trop Dis; 2013; 7(6):e2162. PubMed ID: 23785526
    [No Abstract]   [Full Text] [Related]  

  • 20. The development and use of immunotherapy in Africa.
    Chippaux JP
    Toxicon; 1998 Nov; 36(11):1503-6. PubMed ID: 9792164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.